# Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig in Resectable iCCA

> **NCT06569225** · PHASE2 · NOT_YET_RECRUITING · sponsor: **University Health Network, Toronto** · enrollment: 40 (estimated)

## Conditions studied

- Cholangiocarcinoma Resectable

## Interventions

- **DRUG:** Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig

## Key facts

- **NCT ID:** NCT06569225
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-12-15
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2024-08-26

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06569225

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06569225, "Gemcitabine/Cisplatin/Nab-Paclitaxel and Rilvegostomig in Resectable iCCA". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06569225. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*